Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 120, Issue -, Pages 111-119Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2017.10.013
Keywords
Biopsy; Brainstem glioma; Chemotherapy; Diffuse pontine intrinsic glioma; Molecular targeted therapy
Categories
Funding
- National Cancer Center, Korea [NCC-1511000-3, NCC-1710871-1]
- Ministry of Health and Welfare, Research Fund [1731340-1]
Ask authors/readers for more resources
Prognosis of diffuse intrinsic pontine glioma (DIPG) is poor, with a median survival of 10 months after radiation. At present, chemotherapy has failed to show benefits over radiation. Advances in biotechnology have enabled the use of autopsy specimens for genomic analyses and molecular profiling of DIPG, which are quite different from those of supratentorial high grade glioma. Recently, combined treatments of cytotoxic agents with target inhibitors, based on biopsied tissue, are being examined in on-going trials. Spontaneous DIPG mice models have been recently developed that is useful for preclinical studies. Finally, the convection-enhanced delivery could be used to infuse drugs directly into the brainstem parenchyma, to which conventional systemic administration fails to achieve effective concentration. The WHO glioma classification defines a diffuse midline glioma with a H3-K27M-mutation, and we expect increase of tissue confirmation of DIPG, which will give us the biological information helping the development of a targeted therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available